Solventum Cuts the Cord: Navigating the 3M Separation and ERP Shift

EAGAN, Minn. – November 05, 2026 – Corporate spin-offs are rarely clean breaks. They are messy, protracted divorces involving the painstaking disentanglement of shared IT infrastructure, human resources, and global supply chains. For Solventum, the healthcare technology giant spun out of 3M in early 2024, that arduous process is finally nearing its end.

On Tuesday, the company reported its third-quarter financial results for 2026, posting net sales of $1.95 billion. At first glance, the headline figures—a 7.0 percent reported sales decline and a 2.8 percent organic drop—might suggest a business struggling to find its footing as an independent entity. However, a closer examination of the systems and accounting mechanics at play reveals a vastly different reality. The dip is not a symptom of failing demand, but rather the mathematical echo of a massive infrastructure overhaul.

Beneath the surface noise of GAAP losses and supply chain timing distortions, Solventum is quietly executing one of the most complex corporate transitions in the modern medtech sector, raising its full-year earnings guidance and preparing to reshape its portfolio for the future.

Cutting the Cord: The Mechanics of Independence

When a multi-billion-dollar division leaves a conglomerate like 3M, it doesn't immediately stand on its own. It relies on Transition Service Agreements (TSAs)—temporary contracts where the parent company continues to provide essential back-office functions while the new entity builds its own.

Solventum announced this quarter that it has successfully exited approximately 90 percent of its TSAs with 3M. This is a monumental operational milestone. It signifies that the company has largely replaced the borrowed corporate scaffolding with its own permanent infrastructure.

More critically, Solventum confirmed the completion of its largest Enterprise Resource Planning (ERP) system cutover. An ERP system is the central nervous system of any global manufacturing operation, dictating everything from raw material procurement to final customer billing. Migrating these systems while the business is running is akin to performing a heart transplant on a marathon runner mid-race.

"Solventum delivered third quarter results ahead of our expectations, with every segment contributing, even as we completed our largest ERP cutover; we expect to be near the top end of our full-year organic sales growth range and are raising our full-year adjusted earnings per share outlook," said Bryan Hanson, chief executive officer of Solventum. "With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to accelerate sales growth and expand margins."

Beyond the Noise: Unpacking the ERP Distortion

To understand the 7.0 percent revenue drop in the third quarter, one must look at the second quarter. Knowing that the ERP cutover would require temporary system blackouts and potential shipping delays in Q3, Solventum and its distribution partners executed a classic supply chain maneuver: they pulled orders forward.

Customers stockpiled inventory in Q2 to ensure they wouldn't face shortages during the Q3 system migration. This resulted in roughly $125 million in advance orders inflating the second quarter's numbers, creating a massive 9.5 percent organic growth rate for that period.

Naturally, because those distributors were already fully stocked, they ordered less in the third quarter. This reversal created an expected 630-basis-point headwind. When stripping away this ERP timing distortion and adjusting for planned product line exits, Solventum's normalized organic growth for the third quarter actually sat at a healthy 4 percent.

This underlying resilience was reflected in the bottom line. While the company reported a GAAP net loss of $12 million—driven heavily by restructuring costs and the amortization of acquisition-related intangible assets—its adjusted diluted earnings per share reached $1.45. This performance beat internal expectations, prompting management to raise its full-year 2026 adjusted EPS guidance to a range of $7.20 to $7.30, up from the prior $7.10 to $7.20 window. Furthermore, the company generated $97 million in free cash flow, bolstered by a tariff refund, proving that the core cash-generation engine remains intact.

The 'Transform for the Future' Mandate

With the ERP migration complete and the 3M TSAs largely in the rearview mirror, Solventum is now pivoting from disentanglement to optimization. This transition is being driven by its "Transform for the Future" program, a comprehensive restructuring initiative designed to eliminate stranded costs and build a leaner, standalone cost structure.

In the third quarter alone, the company recorded significant restructuring charges associated with this program. These initiatives typically encompass workforce reductions, the consolidation of management layers, and facility rationalization. By shedding the bureaucratic weight inherited from its conglomerate days, Solventum aims to drive long-term margin expansion.

The goal is not merely cost-cutting, but resource reallocation. By streamlining operations in legacy product lines, the company frees up capital to invest in high-growth areas, such as advanced wound care technologies. The recent FDA clearance for the combined use of Restrata and V.A.C. Therapy—integrating Acera Surgical's technology into Solventum's portfolio—demonstrates how this freed-up capital is already being deployed to drive clinical innovation.

Portfolio Pruning: The Fate of Health Information Systems

As Solventum optimizes its cost structure, it is also taking a hard look at its asset mix. The most glaring outlier in its portfolio is the Health Information Systems (HIS) segment.

Unlike the MedSurg and Dental segments, which manufacture physical medical devices and consumables, HIS is a pure-play software business focused on revenue cycle management, clinical documentation, and data visualization. In the third quarter, HIS proved its standalone durability, posting 4.4 percent organic growth entirely unaffected by the physical supply chain disruptions of the ERP cutover.

However, software and medtech operate on fundamentally different business models, requiring different sales motions, R&D cycles, and capital allocation strategies. Recognizing this, Solventum has initiated a strategic review of the HIS business, openly exploring alternatives that include a potential divestiture.

Industry analysts note that healthcare IT assets, particularly those with recurring revenue streams and high customer retention like Solventum's HIS unit, are highly coveted by private equity sponsors and larger strategic software players. A sale of this high-margin unit could command a premium valuation, providing Solventum with a massive influx of capital to pay down debt, fund future medtech acquisitions, or return value to shareholders.

As 2026 draws to a close, Solventum is no longer just a "former 3M division." It has survived the operational gauntlet of its separation. With its digital infrastructure now modernized, its corporate ties severed, and its portfolio undergoing rigorous strategic review, the company is finally stepping out of the shadows of its parent and defining its own architecture for global progress.